These studies underscore the SNHG3/miR-485-5p axis as a common oncogenic pathway in glioma and breast cancer, suggesting SNHG3 as a potential diagnostic and therapeutic target in these malignancies. This evidence concerns the gene SNHG3 and central nervous system cancer.